Complications of Assisted Reproductive Technologies

Published on 10/04/2015 by admin

Filed under Surgery

Last modified 10/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2235 times

Chapter 40 Complications of Assisted Reproductive Technologies

OVARIAN HYPERSTIMULATION SYNDROME

OHSS is the most common and potentially serious complication of ovarian hyperstimulation for ART procedures, especially in vitro fertilization (IVF). This syndrome consists of ovarian enlargement in conjunction with a continuum of symptoms, depending on severity (Fig. 40-1). In the mildest cases, the patient experiences only pelvic discomfort and nausea. More serious cases are associated with vomiting, abdominal distension, and ascites. The most severe cases can result in respiratory distress, oliguria, hemoconcentration, and thrombosis. In rare cases, death has been reported.

Recognition of high-risk patients, judicious management of follicular stimulation, and aggressive management early in the course of the syndrome are necessary to minimize the incidence and severity of OHSS.

Incidence

The vast majority of OHSS cases occur in association with ovarian stimulation with injectable gonadotropins. Only occasional cases have been observed after clomiphene citrate administration, and very rare cases have been reported during the first trimester of pregnancy resulting from spontaneous unstimulated ovulation.1,2 Sporadically reported cases of familial spontaneous OHSS may be due to a mutation in the follicle-stimulating hormone (FSH) receptor, leading to hypersensitivity of the corpus luteum to human chorionic gonadotropin (hCG).3,4 However, the great majority of cases develop after use of injectable gonadotropins for ovarian hyperstimulation before in vitro fertilization (IVF).

The actual frequency of OHSS varies depending on patient factors, surveillance methods, and management approaches. Mild cases occur in as many as 30% or more of patients undergoing controlled ovarian hyperstimulation with gonadotropins for IVF and often go unrecognized due to the benign nature of the signs and symptoms.5 In general, less than 5% of patients undergoing IVF would be expected to develop moderate symptoms and less than 1% will develop severe symptoms.6,7 It remains unclear why many high-risk induction cycles do not result in severe OHSS while others do.

Pathogenesis

OHSS is the result of excessive follicular response during the follicular phase, but manifests exclusively during the luteal phase following a surge in luteinizing hormone (LH) or ovulatory dose of hCG. The severity and duration is intensified by additional doses of exogenous hCG for luteal support and rising levels of endogenous hCG if the patient becomes pregnant.1,5,8

Vasoactive Substances

OHSS is the result of amplification of normal ovulatory physiology. IVF stimulation protocols commonly result in maturation of upwards of 10 to 20 follicles of varying size on each ovary. OHSS is triggered by release of vasoactive substances in response to hCG or LH. These vasoactive substances cause increased capillary permeability, leading to third spacing of fluid, hemoconcentration, and reduced vascular volume.

Possible participants in the pathogenesis of OHSS include vascular endothelial growth factor (VEGF), prostaglandins, other members of the cytokine family, and nitric oxide, as well as components of the renin and the angiotensin system, especially angiotensin II.913 All of these are recognized participants in the normal physiology of folliculogenesis and luteogenesis.14,15

The primary mediator of increased vascular permeability associated with OHSS appears to be the cytokine VEGF.9,10 VEGF is secreted by granulosa and theca cells in the late follicular phase. Neoangiogenesis, essential to folliculogenesis and especially to luteogenesis, is induced largely by VEGF.1113

Ovarian hyperstimulation syndrome is most commonly thought to be the result of vascular hyperpermeability caused by excessive VEGF-induced changes associated with extreme neoangiogenesis. The expression of VEGF by granulosa cells has been shown to be up-regulated by hCG, and unbound levels of VEGF correlate with the severity of OHSS.16,17 Inhibition of VEGF is associated with improvement in vascular permeability.18,19 Evidence indicates that supernumerary follicles are the predominant source of superphysiologic quantities of VEGF in patients who develop OHSS.20 VEGF acting directly or indirectly in concert with other factors may diffuse into the peritoneal cavity, resulting in increased permeability of diffuse mesothelial vessels. Removal of these substances by paracentesis may facilitate reduction of capillary hyperpermeability, resulting in the observed improvement in the clinical sequelae.21

Risk Factors

No single clinical characteristic or combination of characteristics is 100% predictive of OHSS. However, the incidence is increased by any factor that increases ovarian response (Table 40-1). Patients at highest risk for severe OHSS are those who meet the folowing criteria:

Table 40-1 Risk Factors for Ovarian Hyperstimulation Syndrome (OHSS)

Younger age
Low body mass index
Polycystic ovary syndrome

hCG luteal phase supplementation Previous OHSS

For patients with both of these risk factors, the incidence of severe OHSS has been reported to be as high as 80%.26

The occurrence of OHSS is more closely correlated with degree of ovarian stimulation than it is with the dose and duration of gonadotropins.2729 OHSS occurs more commonly in women with ovaries that are highly sensitive to FSH stimulation, specifically young women and women with polycystic ovary syndrome (PCOS).28,30 Higher doses of gonadotropin are also associated with an increased incidence of OHSS, but only to the extent that higher doses result in more vigorous ovarian stimulation.29 The presence of a large number of follicles, particularly small and moderate-sized follicles, at the time of initial hCG is a positive risk factor for OHSS.2 Estrogen produced by the developing follicles serves as a marker of the degree of ovarian hyperstimulation. High estrogen levels in excess of 4000 pg/mL are of particular concern in the presence of numerous small to medium-sized follicles in contrast to a smaller number of exclusively large or mature follicles.1,28,31

Modified from Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 58:249–261, 1992.

Prevention

Avoidance of Excessive Stimulation

Although it is not possible to prevent all cases of hyperstimulation syndrome, recognition of high-risk patients followed by judicious management of gonadotropin therapy to avoid excessive stimulation can reduce the incidence of OHSS. Menotropin doses should be carefully considered for each patient based on her clinical characteristics. Lower doses and more frequent monitoring should be considered for those patients who are most likely to respond aggressively, especially young patients and those with PCOS. Frequent, sometimes daily, surveillance of serum estradiol levels and follicular growth can facilitate modulation of gonadotropin doses, limiting the rate of estrogen rise without a detrimental effect on follicular growth.

If rapidly rising estrogen levels reach or threaten to become unacceptably high, withholding the daily dose of gonadotropin can reduce the incidence and severity of OHSS. This approach, coasting, can in some cases result in arrest and atresia of all or most of the follicles; however, in many cases hCG administration can be delayed until the estradiol level returns to a more acceptable level without a detrimental effect on the subsequent oocyte and embryo quality or pregnancy rate.3336 Coasting has been shown to be associated with reduced concentrations of follicular VEGF and a significantly lower incidence of severe OHSS.37 Coasting is most successful when the serum estradiol has exceeded 3000 pg/mL and the lead follicle has reached a diameter larger than 14 mm. If growth of the lead follicles continues, administration of hCG can be withheld for up to 4 days until the serum estradiol reaches an acceptable level. Prolonged coasting beyond 4 days is associated with a decrease in implantation and pregnancy rates.38

Withholding hCG

Because the clinical signs and symptoms of hyperstimulation will not develop until final follicular maturation and luteinization occur in response to hCG or LH, it is most prudent to withhold the ovulatory dose of hCG in patients who are clearly overstimulated based on follicular number, size, and estrogen level.31,33 Although the decision to drop a cycle ultimately becomes a matter of clinical judgment, in general it is our practice to withhold hCG in the presence of a large number of small follicles and a peak estradiol level in excess of 4000 pg/mL.

Management of OHSS

Diagnosis

Proactive management of patients with early signs and symptoms of OHSS can ameliorate the severity of OHSS.54 Patients generally present with complaints of abdominal bloating, shortness of breath, and nausea. Symptomatic patients should be seen and evaluated promptly. Clinical parameters should include a physical examination, including a chest and abdominal examination (but not a bimanual pelvic examination) as well as a pelvic or abdominal ultrasound for ovarian enlargement or ascitic fluid and to rule out torsion.

Laboratory studies should include complete blood count, electrolytes, BUN, and creatinine. Hemoconcentration (hematocrit >45%) heralds the development of ascites, marginal renal perfusion, and decreasing urine output and increases the risk of thromboembolic events.55

Most patients with OHSS will have some degree of ascites (Table 40-3). Less commonly, patients will develop pleural effusion, which can occur unilaterally (usually on the right) and in the absence of significant abdominal ascites. A high index of suspicion and careful evaluation are important to differentiate this condition from pulmonary embolism.32

Table 40-3 Complications Associated with OHSS

Ascites

Thrombosis

Buy Membership for Surgery Category to continue reading. Learn more here